S-1/A: Aytu BioPharma Files Amended S-1 Registration Statement, Adjusts Offering Fees and Delays Effectiveness

Aytu BioPharma, Inc. filed an Amendment No. 1 to its S-1 Registration Statement, primarily to update the filing fee table for a proposed offering of common stock and prefunded warrants, and to delay the effective date.

Summary

• This document is Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-287728) filed by Aytu BioPharma, Inc. on June 5, 2025.
• The amendment is an 'exhibits-only filing' specifically to amend Exhibit 107, which details the Calculation of Filing Fee Table.
• The prospectus from the original S-1 filing remains unchanged and has been omitted from this amendment.
• The proposed maximum aggregate offering price for the securities, including Common Stock and Prefunded Warrants, is $13,800,000.
• The registration fee for this offering is calculated at $2,112.78, based on a fee rate of 0.00015310.
• Aytu BioPharma previously paid $1,837.20 for a transaction with a total offering amount of $12,000,000, resulting in a net fee due of $275.58.
• The registration statement also covers any additional shares issuable due to share splits, share dividends, recapitalizations, or similar transactions, as per Rule 416.
• The proposed maximum aggregate offering price of Common Stock will be reduced on a dollar-for-dollar basis based on the offering price of any prefunded warrants issued, and vice-versa.

Sentiment

Score: 5

Explanation: The document is a procedural amendment to a registration statement, primarily updating filing fees and delaying the effective date. It contains no new operational or financial performance data, thus maintaining a neutral sentiment.

Positives

• The company is actively pursuing a capital raise, indicating efforts to secure funding for its operations or strategic initiatives.

Negatives

• The effective date of the registration statement is being delayed, which introduces uncertainty regarding the timing of the proposed capital raise.

Risks

• Potential dilution for existing shareholders due to the proposed offering of common stock and prefunded warrants.
• Uncertainty surrounding the effective date of the registration statement could impact the company's ability to access capital in a timely manner.

Future Outlook

The proposed sale to the public is expected to commence as soon as practicable after the effective date of this registration statement. However, the effective date is currently delayed until the registrant files a further amendment or the Commission determines its effectiveness.

Management Comments

• "The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission acting pursuant to said Section 8(a), may determine."

Industry Context

As a biopharmaceutical company, Aytu BioPharma's capital raising efforts are typical for the industry, which often requires significant funding for research, development, and commercialization of products. The use of common stock and prefunded warrants is a common financing mechanism in the biotech sector to raise capital while managing immediate dilution.

Management Changes

Corporate Governance

Related Party Transactions

• Amended and Restated Employment Agreement with Joshua R. Disbrow (Chief Executive Officer) dated February 13, 2023.
• Amended and Restated Employment Agreement with Jarrett T. Disbrow dated March 20, 2023.
• Amended and Restated Employment Agreement with Greg Pyszczymuka dated March 21, 2023.
• Amended and Restated Employment Agreement with Ryan J. Selhorn (Chief Financial Officer) dated November 11, 2024.
• Separation and Release Agreement with Mark K. Oki dated December 1, 2024.

Stakeholder Impact

• Shareholders: Potential for dilution from the proposed offering of common stock and warrants. The delay in the effective date introduces uncertainty regarding the timing of the capital raise.
• Management/Employees: Employment agreements and equity incentive plans are in place, indicating ongoing compensation and retention strategies.

Next Steps

• The registrant must file a further amendment specifically stating that the registration statement shall become effective.
• The Securities and Exchange Commission (SEC) may determine the effective date of the registration statement.
• The proposed sale to the public will commence as soon as practicable after the registration statement becomes effective.

Key Dates

Keywords

Aytu BioPharma, S-1/A, SEC Filing, Registration Statement, Common Stock, Prefunded Warrants, Capital Raise, Biopharma, Pharmaceuticals, Equity Offering, Filing Fees